Moderna Therapeutics (United States)

Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolates

ABSTRACT Respiratory syncytial virus (RSV) continues to circulate at high levels despite the introduction of new monoclonal antibodies (mAbs) and vaccines targeting the pre-fusion F (pre-F) protein. We analyzed the viral genome sequences of 133 RSV clinical samples collected duri...

Factors associated with severe COVID-19 outcomes among adults with at least a primary vaccination schedule: A retrospective cohort study from Alberta, Canada

Abstract Background With a large proportion of adults in Canada vaccinated against SARS-CoV-2, it is important to identify who remain at risk for severe COVID-19 outcomes after primary vaccination/additional (booster) doses. Methods Adults (≥18 years) who received at least a prim...